Autopsy report · NCT06245941

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

“Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year 8 months before it stopped.
• 21 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Sponsor type

Industry

Conditions

Myelofibrosis

Interventions

TQ05105 tablets; TQB3909 tablets

Participants

21

Sites

5

Countries

China

Trials that died the same way

• Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
  “This was a sponsor decision and was not a consequence of any safety concern” (73% match in meaning)
• Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
  “Sponsor decision to prematurely stop the study, not linked to any safety concern.” (71% match in meaning)
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
  “This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.” (71% match in meaning)
• Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
  “This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.” (71% match in meaning)
• Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
  “This study was closed to enrollment as of 13 May 2011 due to business reasons. Premature closure was not prompted by any safety or efficacy concerns.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.